Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension access study of extended-release guanfacine for European children and adolescents with ADHD
NL-OMON39256Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of guanfacine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Primary endpoints: Treatment-emergent adverse events, Blood pressure and pulse and 3 more. Started Aug 2012; status: active, not recruiting.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NL-OMON39256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39256.